The combination of anti-KIR monoclonal antibodies with anti-PD-1/PD-L1 monoclonal antibodies could be a critical breakthrough in overcoming tumor immune escape in NSCLC

The combination of anti-KIR monoclonal antibodies with anti-PD-1/PD-L1 monoclonal antibodies could be a critical breakthrough in overcoming tumor immune escape in NSCLC

Yayi He,1,2,* Sangtian Liu,1,* Jane Mattei,3 Paul A Bunn Jr,2 Caicun Zhou,1 Daniel Chan2 1Department of Medical Oncology, Shanghai Pulmonary Hospital, Tongji University Medical School Cancer Institute, Tongji University School of Medicine, Shanghai, China; 2Division of Medical Oncology, Department...

Full description

Bibliographic Details
Main Authors: He YY, Liu ST, Mattei J, Bunn Jr PA, Zhou CC, Chan D
Format: Article
Language:English
Published: Dove Medical Press 2018-04-01
Series:Drug Design, Development and Therapy
Subjects:
non-small cell lung cancer
immune therapy
HLA/KIR
PD-1/PD-L1
tumor immune escape
Online Access:https://www.dovepress.com/the-combination-of-anti-kir-monoclonal-antibodies-with-anti-pd-1pd-l1--peer-reviewed-article-DDDT

Internet

https://www.dovepress.com/the-combination-of-anti-kir-monoclonal-antibodies-with-anti-pd-1pd-l1--peer-reviewed-article-DDDT

Similar Items